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General practice
Biochemical diagnosis of ventricular dysfunction in
elderly patients in general practice: observational study
H Smith, R M Pickering, A Struthers, I Simpson, D Mant
Abstract
Objective To investigate the usefulness of measuring
plasma concentrations of B type natriuretic peptide in
the diagnosis of left ventricular systolic dysfunction in
an unselected group of elderly people.
Design Observational study.
Setting General practice with four centres in Poole,
Dorset.
Participants 155 elderly patients aged 70 to 84 years.
Main outcome measures Diagnostic characteristics of
plasma B type natriuretic peptide measured by
radioimmunoassay as a test for left ventricular systolic
dysfunction assessed by echocardiography.
Results The median plasma concentration of B type
natriuretic peptide was 39.3 pmol/l in patients with
left ventricular systolic dysfunction and 15.8 pmol/l in
those with normal function. The proportional area
under the receiver operator curve was 0.85. At a
cut›off point of 18.7 pmol/l the test sensitivity was
92% and the predictive value 18%.
Conclusions Plasma concentration of B type
natriuretic peptide could be used effectively as an
initial test in a community screening programme and,
possibly, using a low cut›off point, as a means of ruling
out left ventricular systolic dysfunction. It is, however,
not a good test to “rule in” the diagnosis, and access to
echocardiography remains essential for general
practitioners to diagnose heart failure early.
Introduction
Diagnosis in general practice is difficult, and the clinical
diagnosis of left ventricular dysfunction is no
exception. It is known that morbidity and mortality can
be reduced by treating patients with ventricular
dysfunction with angiotensin converting enzyme
inhibitors. There is, however, no simple and reliable
clinical method of identifying such patients. The classic
signs of raised jugular venous pressure and fine basal
crepitations become evident at the later stages of heart
failure when there is severe dysfunction. The clinical
correlates of less severe dysfunction are of lesser diag›
nostic value as no identified clinical symptom or sign is
both sensitive and specific.1 Inappropriate treatment of
ventricular dysfunction in primary care (due to both
underdiagnosis and overdiagnosis) is leading to
unnecessary morbidity and mortality.2
Recent interest has been shown in the utility of
assays of natriuretic peptide for screening and
diagnosing heart failure. The concept of a biochemical
test for heart failure is appealing to general practition›
ers, who are often faced with breathless and fatigued
patients. Several natriuretic peptides have been consid›
ered for this role. C terminal and N terminal atrial
natriuretic peptides are secreted in response to the
stretch that occurs with increased left atrial pressure
associated with heart failure. The natriuretic peptide
that is thought to have most diagnostic value in this
context is the brain or B type (so called because it was
first identified in the porcine brain in 19883). The main
source of this peptide in humans is the cardiac ventri›
cle, and the potential utility of plasma concentrations
as a diagnostic indicator of early ventricular failure has
been reported.4
Measurement of the plasma concentration of B
type natriuretic peptide might be diagnostically useful
in primary care. Cowie et al reported a likelihood ratio
of 6.1 (sensitivity 97%, specificity 84%, cut›off point
22.2 pmol/l) for the diagnosis of heart failure in a
sample of 106 patients with symptoms who were
referred by general practitioners to a rapid access out›
patient clinic.5 McDonagh et al reported a similar like›
lihood ratio of 5.8 (sensitivity 76%, specificity 87%, cut›
off point 5.1 pmol/l) for the diagnosis of left
ventricular systolic dysfunction in an unselected group
of 1653 patients aged 25›74 years who had
participated in the monitoring trends and determi›
nants in cardiovascular disease project.6
There is no doubt about the potential importance
of these findings. Clinical diagnosis of mild and
moderate heart failure is difficult and imprecise in gen›
eral practice. Hospital based echocardiography serv›
ices are often stretched, facilities for echocardiography
are not widely available in the community, and current
technology is not easily mobile. Neither of these
studies, however, included many elderly patients, on
whom the test is most likely to be used in general prac›
tice. It has been argued that impaired renal function
and other comorbidity in elderly patients leads to
raised concentrations of blood B type natriuretic pep›
tide, thus reducing the predictive value of the test in
routine clinical use.7 We aimed to investigate the
usefulness of B type natriuretic peptide in the identifi›
cation of left ventricular systolic dysfunction in an
unselected group of elderly patients.
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Participants and methods
We conducted our study in the context of a prevalence
study of left ventricular systolic dysfunction in elderly
patients. We screened a random sample of 817 elderly
patients aged 70›84 years from general practice (77.4%
of 1056 eligible patients).1 The mean age of the
patients was 75.6 years (SD 3.7 years). Diagnosis was
based on echocardiographic assessment of global and
regional ventricular function, including measurement
of left ventricular ejection fraction. A random sub›
sample of 160 consecutive patients was also asked to
undergo venepuncture. Five samples were unsuitable
for analysis; the results presented are therefore based
on 155 patients.
Sample collection, storage, and assay
A 10 ml sample of venous blood was taken from the
study participants. The sample was put into tubes con›
taining edetic acid as an anticoagulant and 0.5 ml tra›
sylol to prevent breakdown of natriuretic peptide.
Within half an hour the sample was spun in a refriger›
ated centrifuge (4°C) at 3000 rpm for 15 minutes. The
separated plasma was divided into two aliquots and
stored at –20°C until it was transferred to storage at
–70°C at the end of each day or within 24 hours. The
plasma was applied to C8 solid extraction columns,
which were pretreated with 4 ml methanol, 4 ml
distilled water, and 4 ml 1% trifluoroacetic acid. The
columns were then washed with 9 ml of 1%
trifluoroacetic acid and the sample eluted with 4 ml of
95% methanol and 1% trifluoroacetic acid. The eluted
peptides were dried and redissolved in buffer for
analysis using standard commercial kits (Peninsular
Laboratories Europe, St Helen’s, Merseyside). The
interassay and intra›assay coefficients of variation were
14.8% and 9.9% respectively. The laboratory reference
range for B type natriuretic peptide is 2.34›4.43
pmol/l.
Statistical analysis
A receiver operator characteristic curve was drawn, and
we analysed B type natriuretic peptide as a predictor of
left ventricular systolic dysfunction with SPSS (release
9.0). We chose three cut›off points of B type natriuretic
peptide to achieve sensitivity values of at least 90%,
80%, and 70%. For each resulting sensitivity we
calculated specificity and both positive and negative
predictive values. Likelihood ratios for positive and
negative test results are also presented with exact 95%
confidence intervals, calculated in StatXact (release 4).
Results
Figure 1 shows the distribution of plasma concentra›
tions of B type natriuretic peptide in normal elderly
people and in those with left ventricular systolic
dysfunction confirmed by echocardiography. The
median concentration of B type natriuretic peptide was
39.3 pmol/l in patients with ventricular dysfunction
and 15.8 pmol/l in those with normal function.
Figure 2 and the table show the operating
characteristics of B type natriuretic peptide as a
diagnostic test in elderly patients. We show the
trade›off between true positive and false positive rates
by presenting the data as a traditional receiver
operator curve (fig 2). The proportional area under the
curve is 0.85. The table shows the predictive values and
likelihood ratios at specific cut›off points, chosen to
approximate to sensitivities of 90%, 80%, and 70%. At
the lowest cut›off point shown (18.7 pmol/l, sensitivity
91.7%) the predictive value achieved was 18%. Setting
the cut›off point to achieve a sensitivity of 100% would
lower the predictive value further.
Discussion
The measurment of plasma concentrations of B type
natriuretic peptide in elderly patients in general
practice could be an invaluable aid in the diagnosis of
ventricular dysfunction. One of our main concerns was
whether B type natriuretic peptide would maintain its
diagnostic value in elderly patients with multiple
disease in whom it is most likely to be used in primary
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care. There are good theoretical grounds for
suspecting that B type natriuretic peptide might be
increased for reasons other than ventricular dysfunc›
tion in such patients. The test may not perform as well
in elderly as in young patients, but it still works.
Measuring plasma concentrations of B type natri›
uretic peptide has two potential diagnostic uses in a
community setting—for screening populations for the
detection of previously unrecognised heart failure and
as an aid to clinical decision making about a patient
with symptoms. The value of the test is not necessarily
the same for each use. The limitation of plasma B type
natriuretic peptide in a screening programme for eld›
erly patients is its low predictive value. For example, to
identify nine out of 10 patients with ventricular
dysfunction requires a cut›off point at which only one
in five patients testing positive has the condition. B type
natriuretic peptide would therefore have to be used as
a first stage screening examination followed by second
stage screening with echocardiography in a more spe›
cialised setting.
An example of the value of plasma concentrations
of B type natriuretic peptide as a diagnostic test in
patients with symptoms in general practice would be
an elderly patient with breathlessness on walking (pre›
test probability of ventricular dysfunction about 15%).1
The test would not be helpful in confirming a diagno›
sis of ventricular dysfunction in this situation—even
using the cut›off point that maximises the likelihood
ratio of a positive test (26.7 pmol/l, likelihood ratio
3.8), the post›test probability would still be under 40%.
This probability is too low to eliminate the need for
further investigation. Conversely, the test may be useful
for ruling out left ventricular dysfunction. If the test was
negative at a cut›off point of 18.7 pmol/l in the same
patient, the probability in a post›test would be less than
2%. Moreover, it might be possible to choose an even
lower cut›off point at which left ventricular dysfunction
could be effectively ruled out, although our sample size
is insufficient to estimate this point with any precision.
One important point that emerged during the
study is that measuring plasma concentrations of B
type natriuretic peptide is feasible in general practice.
Although the blood samples in this study were
processed rapidly, being centrifuged on site before
freezing to − 20°C within 30 minutes and later being
transferred to storage at − 70°C, it has now been
shown that this is unnecessary. B type natriuretic pep›
tide is stable in routine tubes containing ethylene›
diamine tetraacetic acid and stored at room tempera›
ture for at least six hours—sufficient time for the
sample to be transported from general practice to the
hospital laboratory without the need for prior spinning
or freezing.8
B type natriuretic peptide has diagnostic value in
elderly patients in routine general practice. It could be
used effectively as an initial test in a community
screening programme and, possibly, using a low cut›off
point, as a means of ruling out a diagnosis of left ven›
tricular systolic dysfunction. It is, however, not a good
test to “rule in” the diagnosis. The immediate implica›
tion for NHS provision is that even if a B type
natriuretic peptide blood test is done, access to
echocardiography remains essential for general practi›
tioners to make an early diagnosis of heart failure.
This report is based on an echocardiographic screening study
conducted in the Adam practice, Dorset, under Dr G S Liddiard.
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What is already known on this topic
No simple or reliable method is available for the clinical diagnosis of
early left ventricular systolic dysfunction in general practice
Measurement of plasma concentrations of natriuretic peptides, for
example the B type, may be of diagnostic value, but previous studies of
diagnostic utility have focused on young patients whereas the burden
of disease is among elderly people
What this study adds
The test performs less well in elderly than young patients, but it still
works
In elderly people measurement of plasma concentrations of B type
natriuretic peptide may be helpful as an initial community screening
test and to rule out the diagnosis of early left ventricular systolic
dysfunction in patients with symptoms in general practice
Diagnostic confirmation of early left ventricular systolic dysfunction in
patients with symptoms or in those screened in general practice still
requires access to echocardiography
Operating characteristics of different cut›off points for plasma concentrations of B type
natriuretic peptide. Values are percentages (numbers) of patients unless stated
otherwise
Characteristics
B type natriuretic peptide (pmol/l)
>18.7 >19.8 >26.7
Sensitivity 92 (11/12) 83 (10/12) 75 (9/12)
Specificity 65 (93/143) 70 (100/143) 80 (115/143)
Positive predictive value 18 (11/61) 19 (10/53) 24 (9/37)
Negative predictive value 99 (93/94) 98 (100/102) 98 (115/118)
Likelihood ratio* (95% CI) 2.6 (1.4 to 4.1) 2.8 (1.3 to 4.7) 3.8 (1.6 to 7.6)
Likelihood ratio† (95% CI) 0.13 (0.00 to 0.55) 0.24 (0.11 to 0.69) 0.31 (0.03 to 0.72)
*Positive test result.
†Negative test result.
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